Your browser is no longer supported. Please, upgrade your browser.
DVAX Dynavax Technologies Corporation monthly Stock Chart
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-1.08 Insider Own0.10% Shs Outstand109.82M Perf Week-9.98%
Market Cap457.54M Forward P/E- EPS next Y-0.51 Insider Trans- Shs Float108.02M Perf Month5.60%
Income-96.50M PEG- EPS next Q-0.23 Inst Own80.80% Short Float26.62% Perf Quarter-33.49%
Sales37.60M P/S12.17 EPS this Y15.10% Inst Trans9.09% Short Ratio8.78 Perf Half Y-14.26%
Book/sh0.63 P/B6.59 EPS next Y42.00% ROA-31.60% Target Price- Perf Year-28.82%
Cash/sh1.61 P/C2.58 EPS next 5Y- ROE-261.40% 52W Range1.80 - 12.44 Perf YTD-27.45%
Dividend- P/FCF- EPS past 5Y8.90% ROI-72.10% 52W High-66.64% Beta1.26
Dividend %- Quick Ratio3.50 Sales past 5Y26.10% Gross Margin61.20% 52W Low130.56% ATR0.31
Employees231 Current Ratio4.40 Sales Q/Q26.40% Oper. Margin- RSI (14)48.25 Volatility5.67% 7.98%
OptionableYes Debt/Eq2.59 EPS Q/Q108.00% Profit Margin- Rel Volume0.60 Prev Close4.20
ShortableNo LT Debt/Eq2.59 EarningsNov 05 AMC Payout- Avg Volume3.28M Price4.15
Recom1.70 SMA200.53% SMA50-5.75% SMA200-22.75% Volume2,001,670 Change-1.19%
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Nov-17-20 04:05PM  
Nov-16-20 06:00AM  
Nov-10-20 05:33AM  
Nov-07-20 08:58AM  
Nov-06-20 07:33AM  
Nov-05-20 06:35PM  
Nov-03-20 09:56AM  
Nov-02-20 04:05PM  
Oct-30-20 08:14AM  
Oct-29-20 12:35PM  
Oct-27-20 05:50PM  
Oct-22-20 04:05PM  
Oct-21-20 05:50PM  
Oct-19-20 03:30PM  
Oct-13-20 07:09AM  
Oct-07-20 10:00AM  
Oct-02-20 05:50PM  
Sep-24-20 04:05PM  
Sep-15-20 08:58AM  
Sep-14-20 09:53AM  
Sep-08-20 03:14PM  
Sep-07-20 11:08AM  
Sep-05-20 08:02AM  
Aug-31-20 04:10PM  
Aug-13-20 08:00AM  
Aug-12-20 12:12PM  
Aug-11-20 11:27AM  
Aug-10-20 08:38AM  
Aug-06-20 08:20PM  
Aug-05-20 11:56AM  
Aug-03-20 03:53PM  
Jul-30-20 04:05PM  
Jul-29-20 12:33PM  
Jul-28-20 08:19AM  
Jul-27-20 10:53AM  
Jul-23-20 05:50PM  
Jul-21-20 04:10PM  
Jul-17-20 11:42AM  
Jul-16-20 10:02AM  
Jul-14-20 11:28AM  
Jul-13-20 05:45PM  
Jul-10-20 04:01PM  
Jul-08-20 10:09AM  
Jul-07-20 09:43AM  
Jul-05-20 09:16AM  
Jun-30-20 11:30AM  
Jun-22-20 11:28AM  
Jun-21-20 11:15PM  
Jun-19-20 07:41AM  
Jun-15-20 11:45AM  
Jun-10-20 09:30AM  
Jun-09-20 08:00AM  
Jun-04-20 06:37PM  
Jun-01-20 04:00PM  
May-30-20 05:12PM  
May-29-20 04:29PM  
May-28-20 04:05PM  
May-27-20 04:05PM  
May-22-20 10:19AM  
May-21-20 09:00PM  
May-20-20 01:18PM  
May-19-20 04:08PM  
May-14-20 09:24AM  
May-09-20 02:31PM  
May-07-20 04:10PM  
Apr-30-20 12:33PM  
Apr-28-20 04:10PM  
Apr-23-20 04:10PM  
Apr-20-20 08:15AM  
Apr-17-20 08:44AM  
Apr-16-20 07:30AM  
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janssen RobertSenior Vice PresidentJul 17Sale11.0950,000554,500127,266Jul 20 07:42 PM
Hack Andrew A. F.DirectorMay 27Buy5.001,000,0005,000,0008,525,000May 28 05:13 PM
Janssen RobertSenior Vice PresidentMay 19Sale6.3315,00094,950177,266May 19 07:05 PM
Janssen RobertSenior Vice PresidentMay 06Sale4.5228,000126,560192,266May 07 06:37 PM
Janssen RobertSenior Vice PresidentMay 05Sale4.439,00039,870220,266May 07 06:37 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.